These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 2054780

  • 1. Binding analysis of the estrogen receptor to its specific DNA target site in human breast cancer.
    Foster BD, Cavener DR, Parl FF.
    Cancer Res; 1991 Jul 01; 51(13):3405-10. PubMed ID: 2054780
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
    Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC.
    Clin Cancer Res; 1999 Feb 01; 5(2):251-6. PubMed ID: 10037172
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Activation of bone morphogenetic protein-6 gene transcription in MCF-7 cells by estrogen.
    Zhang M, Yan JD, Zhang L, Wang Q, Lü SJ, Zhang J, Zhu TH.
    Chin Med J (Engl); 2005 Oct 05; 118(19):1629-36. PubMed ID: 16232348
    [Abstract] [Full Text] [Related]

  • 12. Targeting estrogen responsive elements (EREs): design of potent transactivators for ERE-containing genes.
    Huang J, Li X, Yi P, Hilf R, Bambara RA, Muyan M.
    Mol Cell Endocrinol; 2004 Apr 15; 218(1-2):65-78. PubMed ID: 15130512
    [Abstract] [Full Text] [Related]

  • 13. The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity.
    Wang LH, Yang XY, Zhang X, Mihalic K, Xiao W, Farrar WL.
    Cancer Res; 2003 May 01; 63(9):2046-51. PubMed ID: 12727818
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. NF-kappaB and estrogen receptor alpha interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells.
    Gionet N, Jansson D, Mader S, Pratt MA.
    J Cell Biochem; 2009 Jun 01; 107(3):448-59. PubMed ID: 19350539
    [Abstract] [Full Text] [Related]

  • 17. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
    Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S.
    Breast Cancer Res Treat; 2005 Mar 01; 90(1):65-70. PubMed ID: 15770528
    [Abstract] [Full Text] [Related]

  • 18. T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance.
    Graham ML, Krett NL, Miller LA, Leslie KK, Gordon DF, Wood WM, Wei LL, Horwitz KB.
    Cancer Res; 1990 Oct 01; 50(19):6208-17. PubMed ID: 2400987
    [Abstract] [Full Text] [Related]

  • 19. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.
    Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson JA, Toi M.
    Cancer Res; 2002 Sep 01; 62(17):4849-53. PubMed ID: 12208729
    [Abstract] [Full Text] [Related]

  • 20. Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites.
    Petz LN, Ziegler YS, Schultz JR, Kim H, Kemper JK, Nardulli AM.
    J Steroid Biochem Mol Biol; 2004 Feb 01; 88(2):113-22. PubMed ID: 15084343
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.